Objective To evaluate the efficacy of ranibizumab intravitreal injection in patients with diabetic macu -lar edema (DME) and macular edema caused by retinal vein occlusion (RVO-ME).Methods Twenty-three cases of DME and RVO-ME patients were enrolled in this study .The eligible patients were treated with 0.05 ml intravitreal injec-tion of ranibizumab and followed for 4 weeks.Best corrected visual acuity (BCVA), central subfield thickness (CST), cube average thickness ( CAT) and Amsler grid performance were analyzed .Results Four weeks after the administration of ranibizumab, we found in our patients that 1) BCVA improved;2) CST and CAT decreased;and 3) the rate of abnor-mal Amsler grid examination declined .Spearman correlation analysis showed that CST has no correlation with Amsler grid Results.Conclusion patients with DME and RVO-ME treated with ranibizumab obtained great improvements in vision function in 4 weeks.%目的：评价玻璃体腔单次注射抗血管内皮细胞生长因子药物雷珠单抗治疗糖尿病黄斑水肿DME和视网膜静脉阻塞（ RVO）性黄斑水肿的短期疗效。方法在安徽医科大学第一附属医院规律随访符合纳入和排除标准的DME和RVO黄斑水肿者23只眼。患眼给予玻璃体腔注射0．05 ml雷珠单抗注射液，治疗后2 d复查最佳矫正视力，治疗后4周进行复查最佳矫正视力、黄斑中心凹厚度、黄斑区平均厚度和Amsler表。结果治疗后2 d与治疗前相比，视力提高（ t ＝4．632， P ＜0．001）。治疗后4周与治疗前相比，黄斑中心凹厚度降低（ t ＝10．165， P＜0．001），黄斑区平均厚度降低（ t ＝3．368， P ＝0．003），视力提高（ t ＝7．281， P ＜0．001）。 Amsler表阳性率下降（χ2＝8．013， P ＝0．005）。差异均具有统计学意义。治疗后4周与治疗后2 d相比，视力提高，差别有统计学意义（ t ＝5．271， P ＜0．001）。黄斑中心凹厚度与Amsler表阳性率的相关性分析：无统计学意义（相关系数0．128， P ＝0．398）。结论玻璃体腔单次注射雷珠单抗对DME和RVO黄斑水肿在4周内有效。
展开▼
